Kymera Therapeutics (KYMR) Tops Q4 EPS by 15c

Kymera Therapeutics (NASDAQ: KYMR) reported Q4 EPS of ($0.25), $0.15 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $47.9 million versus the consensus estimate of $41.94 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Kymera Therapeutics (KYMR) PT Raised to $136 at Truist Securities
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• MSC Industrial (MSM) Tops Q3 EPS by 17c, Beats on Revenue